Transdermal Estrogen Patch vs Oral Estrogen: Stroke Risk Comparison

Key Evidence from Guidelines

The American Heart Association/American Stroke Association guidelines state that transdermal estrogen formulations, especially at low doses, do not increase stroke risk compared to oral estrogen formulations, which are associated with a clear increased risk of stroke 1
Oral estrogen-containing menopausal hormone therapy is associated with excess stroke risk, with estimates of 79 additional strokes per 10,000 women treated with estrogen-only formulations and 52 additional strokes per 10,000 women with estrogen/progestin formulations 1
Meta-analyses of randomized controlled trials show oral hormone therapy increases stroke risk with a relative risk of 1.32 (95% CI, 1.12-1.56) 1

Oral estrogen undergoes first-pass hepatic metabolism, which increases production of clotting factors and affects multiple hemostatic pathways in a prothrombotic direction 2

Every 10 μg increase in oral estrogen dose is associated with an odds ratio of 1.19 (95% CI, 1.16-1.23) for stroke 4
Oral contraceptives with <50 μg estrogen have lower stroke risk (RR 2.08) compared to preparations with higher estrogen content (RR 4.53) 4

The American College of Cardiology recommends that transdermal estrogen should be preferred over oral estrogen for most women requiring hormone therapy, particularly those with cardiovascular risk factors including hypertension 6
For women <60 years of age within 10 years of menopause onset with low cardiovascular risk, transdermal formulations at the lowest effective dose are the safest option 1
Transdermal estrogen is particularly important for women with stroke risk factors (age >35 years, tobacco use, hypertension, or migraine with aura) 5

Absolute contraindications to any estrogen therapy (oral or transdermal) include history of stroke or transient ischemic attack 1
Absolute contraindications to any estrogen therapy (oral or transdermal) include known thrombophilic disorders 7
Absolute contraindications to any estrogen therapy (oral or transdermal) include history of breast cancer or estrogen-dependent neoplasia 7

For women requiring estrogen therapy for menopausal symptoms, first-line treatment should be transdermal estrogen at the lowest effective dose if patient meets criteria (age <60, within 10 years of menopause, low cardiovascular risk) 1
For women with intact uterus, progestin should be added to any estrogen formulation to prevent endometrial hyperplasia 7